HOUSTON, TEXAS (August 23, 2018) - Houston medical device developer Procyrion Inc. today announced they have won the Most Innovative Heart Pump Technology award in the 2018 Global Healthcare and Pharmaceutical Awards for their device, Aortix™, a catheter-deployed circulatory support device designed initially to address cardiorenal syndrome in heart failure patients. The award celebrates the contributions made by organizations and individuals operating within the world’s most vital industries.
Procyrion’s award winning technology, Aortix, with a pump thinner than a #2 pencil, is the first percutaneous mechanical circulatory support (pMCS) device whose design is uniquely suited to address cardiorenal syndrome in chronic heart failure patients who are failing medical therapy, but not sick enough for risky surgical interventions like heart transplants or LVADs. The unique placement of the small but powerful micropump in the descending thoracic aorta is intended to simultaneously unload the heart and support the kidneys by accelerating native blood flow in the aorta.
“We believe Aortix has the potential to offer a new treatment option for millions of patients with chronic heart failure, in particular the underserved patients who also have kidney disease,” said Eric S. Fain, M.D., CEO of Procyrion. “This recognition further validates all of the hard work our team has put in to developing a life altering technology.”
The Global Healthcare and Pharma awards are given solely on merit and are awarded to commend those most deserving for their ingenuity and hard work, distinguishing them from their competitors and proving them worthy of recognition.
Procyrion Inc., headquartered in Houston, Texas, is developing the first percutaneous mechanical circulatory support (pMCS) device to address the significant unmet clinical needs of cardiorenal syndrome in the large chronic heart failure population. Aortix is not approved for sale in any geography. Please visit www.procyrion.com for more information.